Welcome to Chiesi
USA
Home page > News
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
22-04-2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
05-03-2024
Chiesi Global Rare Diseases Announces Updated U.S. Prescribing Information for FERRIPROX® (deferiprone)
03-12-2021
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Canada for the Treatment of Iron Overload in Sickle Cell Disease
15-10-2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease
15-10-2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease
14-10-2021
Chiesi Global Rare Diseases Announces Approval of FERRIPROX® (deferiprone) in Brazil for the Treatment of Iron Overload in Sickle Cell Disease
13-09-2021
Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease Companies Announce Topline Results from Interim Analysis of Phase III BALANCE Clinical Trial
02-06-2021
Chiesi USA, Inc. Earns 2021 Life Sciences Award by Triangle Business Journal for second consecutive year
24-05-2021
Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease
01-05-2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA
28-04-2021
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
26-02-2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Positive Topline Results from BRIGHT Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 mg/kg every Four Weeks for Treatment of Fabry Disease
23-02-2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
10-02-2021
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease
30-12-2020
Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for Pegunigalsidase Alfa for Proposed Treatment of Fabry Disease
23-12-2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease
27-11-2020
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
17-09-2020
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the ProposedTreatment of Fabry Disease
25-08-2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
11-08-2020
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
10-07-2020
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
10-07-2020
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
30-06-2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
28-05-2020
